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The treatment of rheumatoid arthritis (RA) has been transformed with the introduction
of biologic disease modifying anti-rheumatic drugs (bDMARD) and more recently,
targeted synthetic DMARD (tsDMARD) therapies in the form of janus-kinase inhibitors.
Nevertheless, response to these agents varies such that a trial and error approach is
adopted; leading to poor patient quality of life, and long-term outcomes. There is thus
an urgent need to identify effective biomarkers to guide treatment selection. A wealth of
research has been invested in this field but withminimal progress. Increasingly recognized
is the importance of evaluating synovial tissue, the primary site of RA, as opposed to
peripheral blood-based investigation. In this mini-review, we summarize the literature
supporting synovial tissue heterogeneity, the conceptual basis for stratified therapy.
This includes recognition of distinct synovial pathobiological subtypes and associated
molecular pathways. We also review synovial tissue studies that have been conducted
to evaluate the effect of individual bDMARD and tsDMARD on the cellular and molecular
characteristics, with a view to identifying tissue predictors of response. Initial observations
are being brought into the clinical trial landscape with stratified biopsy trials to validate
toward implementation. Furthermore, development of tissue based omics technology
holds still more promise in advancing our understanding of disease processes and
guiding future drug selection.
Keywords: rheumatoid arthritis, biologics, JAK inhibitors, synovial tissue, histology, cytokine, gene expression,
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INTRODUCTION
Rheumatoid arthritis (RA) is a complex, genetically and biologically heterogeneous autoimmune
disease. It is characterized by a systemic inflammatory arthritis. The treatment of patients with
RA has evolved considerably in recent years owing to the successful development and widespread
use of biologic disease modifying anti-rheumatic drug (bDMARD) therapy, with more recent
introduction of targeted synthetic DMARDs (tsDMARD) in the form of small molecules inhibitors.
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However, up to 40% patients in clinical trials fail to respond,
also reflected in real-world practice; and a sizeable proportion
fail to achieve the target of therapy, mainly clinical remission
where appropriate or low disease activity (1, 2). Personalized
medicine, i.e., tailoring therapy to individual patient (or, put
simply, “choosing the right drug for the right patient”), has the
potential to improve response rates, but has proven challenging
to implement. If it is to be successful, the identification of reliable
biomarkers will be of prime importance.
In this mini-review, we summarize the evidence for synovial
tissue heterogeneity, and tissue studies that have evaluated
change in cellular and molecular markers following currently
available bDMARD and tsDMARD specifically that could aid
treatment selection.
THE SYNOVIUM, PRINCIPAL TARGET
OF INFLAMMATION
The synovium is the principal target of inflammation in
RA, undergoing marked pathological changes compared to
healthy tissue. The study of RA synovial tissue has offered
insights at a cellular level into multiple aspects of the disease,
from identifying pathogenic processes and pathways (3, 4);
to explaining clinical manifestations. Furthermore, changes
in synovial tissue following successful treatment allow better
understanding of mechanism of drug action (5–7).
Synovial tissue samples can be obtained via arthroscopic or
ultrasound (US)-guided biopsies. The US-guided approach has
been shown to be safe, with reproducible tissue quality/RNA
yield (8), and has the advantage of enabling joint assessment
for synovial thickness (gray-scale score) and vascularity (Power
Doppler-PD), associated with active synovial inflammation (9).
HEALTHY SYNOVIUM
In health, the synovial membrane contains relatively few cells,
consisting of an intimal lining layer of 1–2 cell thickness and
a distinct synovial sublining layer (10). The intima comprises
fibroblast-like synoviocytes (FLS, also known as synovial
fibroblasts or type B synoviocytes) intercalated withmacrophage-
like synoviocytes (MLS, also called type A synoviocytes) (11).
The sub-lining layer is a well-vascularized connective tissue,
containing collagen fibers and evenly dispersed FLS and
MLS (11).
The synovial membrane is key to the structure and function
of the healthy synovial joint. The synovial membrane controls
transport to and from the synovial cavity, thus maintaining the
composition of synovial fluid as well as overall joint homeostasis
and integrity. The intimal lining is particularly important,
as its lack of tight junctions or a true basement membrane
allows the ingress and egress of various cells and proteins (12).
Intimal FLS orchestrate proceedings, controlling the synovial
fluid volume, secreting hyaluronan for lubrication, clearing intra-
articular debris, regulating various immunological processes, and
maintaining the extracellular matrix (ECM) of the sublining (13).
RA SYNOVIUM
In RA, the synovial tissue becomes markedly expanded, with a
striking increase in cellular infiltration. This leads to hallmark
“pannus” formation at cartilage-bone interfaces; pannus can
be composed of macrophages, FLS, leucocytes, plasma cells,
and mast cells (14), and behaves like a locally invasive tumor,
mediating damage and erosion formation in later disease (15).
The intimal lining can expand to 10–20 cells in thickness,
partly due to an increase in FLS, but mostly due to infiltration
by bone marrow-derived MLS recruited from the circulation
(15). Highly activated macrophages send pro-inflammatory
signals to intimal FLS, inducing invasiveness, and to B cells,
which in turn produce various pro-inflammatory mediators.
Paracrine and autocrine signaling networks develop in this way,
further propagating synovitis (16). Sub-lining MLS have been
associated with disease activity (17) and synovial inflammation
measured on magnetic resonance imaging (MRI) (18), and
therefore appear of paramount importance to the inflammatory
joint reaction (19). Proliferation of FLS are a prime cause of
synovial hyperplasia, and major mediators of damage to cartilage
and bone, via both direct and indirect interactions, including
production of inflammatory mediators, adhesion molecules,
proteolytic enzymes and pro-osteoclastogenic factors (13). T
cells are able to establish important crosstalk with antibody-
producing plasma cells (15, 20, 21). When present, CD3+ T
cells in the RA synovium are mostly found in deeper sub-
lining layers, where they may be homogeneously or randomly
distributed, or clustered in follicle-like structures (19). Similarly,
B cells, when present, are mostly organized in follicular
structures, which can act as pro-inflammatory, immunological
niches (19).
HETEROGENEITY OF RA SYNOVITIS
RA synovitis is highly heterogeneous, with diverse cellular and
molecular signatures (22, 23). In recent years distinct patterns
have been recognized, primarily according to the composition,
organization and localization of cellular infiltrates. Studies have
revealed RA synovial ‘pathotypes’ (7, 24), namely, lymphoid,
myeloid, pauci-immune, and fibroid variants (other patterns,
such as granulomatous synovitis, have also been described). The
lymphoid pathotype is characterized by lymphoid infiltrates,
which may be diffuse (small, loosely arranged lymphocyte
clusters) or follicular (large aggregates of lymphocytes organized
in ectopic lymphoid structures). The latter may develop germinal
centers containing T follicular helper (Tfh) cells highly expressing
of programmed cell-death (PD-1), C-X-C chemokine receptor
5 (CXCR5), B-cell lymphoma (Bcl6), and Inducible T cell
costimulator (ICOS) (7, 24, 25). Cellular composition of tissue
defined as myeloid pathotype shows a less abundant B and
T cells aggregates compared to the lymphoid subgroup, and
presence of sublining macrophages. By contrast, the ‘pauci-
immune’ (7) (or ‘low inflammatory’) pathotype shows minimal
infiltrating immune cells (24). The fibroid pathotype has
complete absence of aggregates and little immune infiltration
comprising hyperplastic tissues.
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FLS are also not a uniform population but segregate into
different phenotypes based, in part, on their cytokine profiles
(26). Additionally, functionally distinct disease-associated
subsets of fibroblasts are recognized in RA synovium (27)
including a study based on surface expression of CD34, THY1,
and CDH11 (28). T and B cells infiltrating the inflamed synovium
in RA show the highest degree of qualitative and quantitative
heterogeneity. Whilst the relation of fibroblast subsets to clinical
outcomes remains to be elucidated, these may prove to be
instructive biomarkers.
SYNOVIAL TISSUE GENE EXPRESSION
PROFILES
Early gene expression of RA synovial tissue studies identified
distinct profiles and revealed the presence of multiple activated
signaling pathways (29–31). Perhaps unsurprisingly given
its clinical heterogeneity, expression of molecular signatures
in RA is likewise heterogeneous. Gene expression profiles
can be modulated by disease activity and the burden of
inflammation in synovial tissue (32). Gene expression in RA
synovial (intimal) lining cells specifically has been analyzed
using a laser mediated micro-dissection (LIMM) approach
(33). Data analysis using clustering revealed two distinct
RA subgroups associated with increased expression levels
of inflammation-related genes [compared with osteoarthritis
(OA) control tissue] involved in the tumor necrosis factor
TNF-activated interferon regulatory factor (IRF1)- interferon
(IFN)- signal transducer and activator of transcription 1
(STAT1)- pathway (34). Three molecularly distinct forms of
RA tissues have also been identified by the same group;
the first characterized by genes involved in inflammation
and the adaptive immune response [matrix metalloproteinase
(MMP) 1 and 3 genes, STAT-encoding and -induced genes and
antigen-presenting-cell–related genes], the second characterized
by genes involved in extracellular matrix remodeling (genes
involved in degradation of cartilage and subchondral bone),
and the third with a low-inflammation gene signature similar
to that of osteoarthritis (30, 31). Increased receptor activator
of nuclear factor kappa-B ligand (RANKL) (35) and decreased
osteoprotegerin expression (36) have also been detected in
actively inflamed RA synovial tissue. These findings, along with
the lack of tissue repair signatures, support the hypothesis
of inflammation-driven joint remodeling in RA, characterized
by uncoupling of destructive and reparative processes (37).
A number of transcription factor families, such as nuclear
factor kB (NF-kB) and the activator protein 1 (AP-1), were
established early on as chief regulators of gene expression
in the inflamed synovium (38). Gene expression analysis
of FLS indicates the presence of 2 subtypes, with high-
inflammatory FLS expressing transforming growth factor (TGF)-
β/activin A–inducible genes and FLS from low inflammatory
synovial tissue predominantly expressing growth factor genes
(39). Distinct molecular signatures indicating pathways relating
to T cell-mediated immunity and major histocompatibility
complex (MHC) class II mediated immunity (amongst others)
upregulated in early RA, and pathways relating to the cell cycle
upregulated in later disease (40) have been reported. Similarly
differential gene expression between high and low inflammatory
subsets of RA patients in relation to disease duration has been
observed (29).
GENE EXPRESSION ANALYSIS ACROSS
SYNOVIAL PATHOTYPES
Differential gene expression has also been confirmed across
the RA synovial pathotypes described earlier, providing further
evidence for different molecular mechanisms underlying these
variants. The lymphoid type is characterized by increased
expression of genes associated with B cell and plasmablast
activation and differentiation [including CD19, CD20, X-box
binding protein XBP1, immunoglobulin heavy and light chains,
CD38 and C-X-C motif chemokine ligand 13 (CXCL13)], as
well as the Janus kinase JAK/STAT pathway and interleukin 17
(IL-17) signaling (24). In another study, patients with lymphoid
aggregates again displayed activation of the JAK/STAT pathway,
but also the IL-7 pathway, as well as genes associated with
lymphoid neogenesis [such as CXCL13, C-C chemokine ligand
21 (CCL21), and receptor CCR7 and Lymphotoxin alpha (LTα)]
and B-cell receptor activation, supporting the existence of a
link between tertiary lymphoid structures and the local humoral
response (41). In the myeloid pathotype, activation of NF-κB
pathway genes (including TNFα, IL-1β, IL-1RA, intracellular
adhesion molecule ICAM1, and MyD88), the inflammatory
chemokines CCL2 and IL-8, and granulocyte and inflammatory
macrophage lineage genes (such as S100A12, CD14, andOSCAR)
were identified. In the fibroid pathotype, genes associated with
fibroblast and osteoclast/osteoblast regulation were found to
be involved, including fibroblast growth factor FGF2, FGF9,
BMP6, and osteoprotegerin. Higher expression ofWnt and TGFβ
signaling pathway components, as well as “angiogenesis module”
genes, were also identified (24). The pauci-immune variant shares
characteristics with the aforementioned pathotypes in terms of
inflammatory response gene expression, with “M2 monocyte
module” genes particularly activated (24, 42). Expression of IL-
6, IL-6 receptor components (IL-6R and IL-6ST/gp130), and its
associated signaling component STAT3 was broadly observed
across all phenotypes, consistent with the multiple roles of the
IL-6 pathway in both lymphocyte and fibroblast biology (24, 43).
The existence of different gene expression profiles according to
RA histological pathotype was also confirmed by Klimiuk et al.
who demonstrated increased transcriptional activity of TNFα, IL-
1, IFNγ, IL-10, and TGFβ in follicular synovitis, compared with
diffuse synovitis (44).
Recently, a machine learning algorithm was able to predict
RA synovial gene expression subtype according to 20 histological
features. Three subtypes were pre-identified based on RNA-seq
clustering: high inflammatory, low inflammatory, and mixed.
The high inflammatory subtype showed enrichment of pathways
of immunity, immune cell signaling (including SH2, SH3,
JAK/STAT, and TNF-mediated signaling), immunoglobulins,
chemokines, and cytokines. The low inflammatory subtype was
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defined by enrichment of transforming growth factor β pathways,
glycoprotein synthesis, and cell adhesion genes (45). Distinct
myeloid and lymphoid synovial histological subtypes were not
identified, in contrast to previous studies (24), but the high
inflammatory subtype displayed elevated expression of genes
previously attributed to these in the literature.
SYNOVIAL TISSUE STUDIES TO PREDICT
RESPONSE TO BIOLOGIC AND
TARGETED THERAPIES
General Synovial Tissue Biomarkers of
Response To Therapy
CD68 Macrophage
Effective treatment can modify synovial histology, cytokine and
gene expression, with ineffective treatment having little impact,
thus providing a means to assess for pathological response
(46). Synovial sublining (CD68) macrophage numbers and
macrophage expressed cytokines have been shown to correlate
with disease activity, and change in sublining macrophage to
be the optimal indicator of effective therapy, thus providing
a potential early predictive biomarker of drug response (6,
47, 48). A recent study demonstrated that the transcriptional
profile of isolated RA synovial macrophages highlighted different
subpopulations of patients and identified 6 novel transcriptional
modules that were associated with disease activity and therapy
(49). The authors suggest that transcriptional signatures in
macrophages regardless of location (sublining vs. synovial
lining) predict responsiveness to specific non-biologic and/or
biologic therapies.
Synovial Pathotypes and Response
A study by Dennis et al. suggested myeloid and lymphoid
pathoypes may predict therapeutic sucess with TNF inhibitors
(TNFi) and IL-6-targeted tocilizumab, respectively (24). Analysis
of serum chemokines further suggested these two pathotypes
correlate with raised serum suloble intercellular adhesion
molecule 1 (sICAM) and CXCL13 (sICAM/CXCL13) compared
to high CXCL13/sICAM, respectively. These initial observations
however have not been validated in other cohorts using the serum
correlates (50) indicating the need for additional such synovial
tissue studies. Nevertheless, stratifying patients by synovial
pathotype may inform choice of targeted therapy.
Multiple types of therapies will be discussed in detail below,
these are summarized inTable 1 together with key findings which
indicate response to biologic and synthetic targeted DMARDs.
Anti-cytokine Therapies
Tumor-Necrosis Factor-Inhibitors
Synovial studies have offered useful insights into the mechanism
of action of TNFi. TNFi have been shown to regulate
chemokine and leukocyte trafficking (69) likely explaining the
reduction in the synovial cellular infiltrate observed; with
reductions in synovial tissue expression of IL-6, IL-8, granulocyte
macrophage colony stimulating factor (GM-CSF), macrophage
chemoattractant protein-1 (MCP-1), IL-1β, TNF, and vascular
endothelial growth factor (VEGF) (70).
Several studies have sought to identify predictors of response
to TNF blockade through examination of synovial tissue cytokine
expression. Baseline synovial TNF levels (intimal and sub-lining)
predicted response to infliximab in one study (54), although
another similar study did not reproduce this finding (53).
Decreased sub-lining TNF expression was, however, seen in
responders. A prospective study of 86 patients found higher
proportions of synovial lymphoid aggregates in poor responders
to treatment, despite higher rates of TNFi use. Baseline lymphoid
aggregates were an independent predictor of poor response
in multivariate analysis, and reversal of these histological
changes was seen in over half of treatment responders (57).
Addition of lymphocyte aggregates to sub-lining TNF expression
(54) improved infliximab response prediction, but still only
accounting for 29% variance (71); thus insufficient for clinical
application. An early RA synovial gene expression study found
that mRNA levels pertaining to several inflammatory pathways
were associated with response to TNFi therapy, suggesting a
role for synovial gene expression profiles as response predictors
(72). Another study identified a number of negative predictors
of response to adalimumab, another TNFi biologic, including
baseline synovial expression of IL-7 receptor alpha chain (IL-
7R), CXCL11, IL-18, IL-18 receptor accessory (IL-18rap), and
MKI67 (63). However, a larger gene expression study using whole
synovial tissue samples pre- and post-infliximab did not identify
any predictors, perhaps because of the confounding presence of
lymphoid aggregates (55).
Tocilizumab
Tocilizumab is a clinically effective humanized anti–IL-6R
monoclonal antibody that inhibits membrane IL-6R– and
soluble IL-6R (sIL-6R)–mediated signaling. The aforementioned
study by Dennis et al. (24), suggested lymphoid pathotype
as predictive of response. In another study, paired synovial
tissue biopsies taken at baseline and post-treatment with
tocilizumab showed a significant decrease in the expression
of various chemokines and T-cell activation genes (51). When
compared with gene expression data following other treatments,
results showed strong correlation with methotrexate and B-
cell depleting agent rituximab, but notable differences with
adalimumab (51). A further study of synovial histology post-
tocilizumab demonstrated a complete block of synovial IL-6
and a significant reduction of B-cells, CD29 and phospho-
JNK. ERK was increased in the tocilizumab group compared
to a methotrexate-treated control group, whilst TNF, MMP-3,
and CD68 were similarly expressed in both groups. Therefore,
inhibition of IL-6/CD20/CD29 may be differentially involved in
tocilizumab efficacy compared with methotrexate (52). A more
recent study in 33 early RA patients suggested higher expression
of TNF-induced transcripts in early RA synovitis was associated
with higher disease activity, and predicted poor response to first-
line therapy (that comprised either methotrexate, tocilizumab
or rituximab therapy) (65). Finally, an exploratory study by
Das et al. suggested persistent synovial IL-6 mRNA expression
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TABLE 1 | Rheumatoid synovial tissue studies of biologic and targeted synthetic DMARDs.
Drug RA Population Analysis type Key findings References
ANTI CYTOKINE THERAPY
IL-6
blockade
TCZ 30 early RA (disease
duration <1 year);
treatment-naïve
Gene expression
microarrays, IHC
Significant decrease in the expression of
various chemokines and T-cell activation genes.
(51)
TCZ 10 bDMARD treated RA
patients
10 controls: RA patients on
no bDMARDs
IHC Complete blockade of IL-6.
Inhibition of CD20, CD29, and JNK in MAPK
implicates TCZ efficacy compared with MTX.
(52)
TNF
inhibitors
IFX 32 RA patients IHC Reduction in synovial TNF expression in IFX
responders and non-responders.
Unchanged TNF in extreme
non-responders
(53)
IFX 143 active RA patients IHC Higher intimal and sub-lining TNF expression in
IFX responders vs. non-responders.
(54)
IFX 62 RA patients IHC and gene expression
arrays
Baseline whole synovial biopsy microarray
unable to identify TNFi non-responders.
(55)
ADA 25 RA patients Global gene expression
profiles arrays at T0 and
T16, IHC
Poor response to ADA associated with:
- Upregulation of genes from cell division and
immune responses pathways in poor
responders.
- High baseline synovial expression of IL-7R,
CXCL11, IL-18, IL-18ra), and MKI67.
(56)
Several TNFi 86 RA patients IHC High synovial lymphoid neogenesis, with B and
T cell aggregates, correlated with poorer
clinical outcomes. Reversal of these
aggregates associated with good response.
(57)
CELL-MEDIATED THERAPY
B-Cell
depletion
RTX 13 RA patients IHC, digital image analysis,
gene expression
Significant decrease synovial B cells post-RTX
but not completely depleted compared to
peripheral B cells.
No strong correlation with clinical response.
(58)
RTX 20 RA patients qPCR Responders have higher
expression of macrophage and T cell genes.
Non-responders showed higher expression of
interferon-α and signaling genes.
(59)
RTX 24 RA patients IHC, flow cytometry Significant lower infiltration of CD79+CD20−
plasma cells in the synovium associated with
the reduction in peripheral blood B-cell
repopulation.
(60)
RTX 24 RA patients IHC Clinical response predicted by changes in cell
types other than B cells, mainly number of
synovial plasma cells.
(61)
RTX 17 RA patients IHC RTX treatment associated with rapid decrease
in synovial B cell numbers.
(62)
T-CELL CO-STIMULATION BLOCKADE
ABT 16 RA patients IHC Significant downregulation of pro inflammatory
genes, notably IFNγ.
Only specific reduction in synovial CD20+ B
cells, in responders.
(63)
ABT 20 RA patients
(10 ABA and 10 MTX)
IHC Increase in CD29 and ERK in MAP kinases. (64)
MIXED BDMARD COHORT
NSAIDs and
DMARDs
with/without
bDMARD (ADA,
ETN, IFX, ANK,
RTX)
49 RA patients and 29 RA GeneChip Human Genome
U133 Plus 2.0 Arrays
(Affymetrix, Inc.) ELISA, IHC
A myeloid phenotype (high serum sICAM1/low
CXCL13) prevalent in responders to TNFI
therapy
A lymphoid pathotype (high serum CXCL13/low
sICAM1) prevalent in responders to TCZ.
(24)
(Continued)
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TABLE 1 | Continued
Drug RA Population Analysis type Key findings References
TCZ, MTX, RTX Early RA (mainly <1 year
disease duration), pre- and
post-3 months
TCZ (n =13 and 12
respectively)
or MTX (n = 2 × 8 samples)
TNFi-failure RA pre- and
post 3 months RTX (n = 2
× 12 samples)
GeneChip Human Genome
U133
Plus 2.0., Affymetrix, IHC
Over-expressed baseline tissue
GADD45B and PDE4D in first-line MTX and
bDMARD non- responders
(65)
SMALL INHIBITORS (JAKi)
TOFA 14 RA patients ELISA, IHC, qPCR.
Reduced synovial mRNA expression of MMP1
and MMP3 and IFN-regulated genes.
Clinical improvement correlated with reductions
in STAT1 and STAT3 phosphorylation.
(66)
TOFA Varied/unclear Synovial explants and tissue
culture of primary RASFs,
qPCR, WB, and ELISA
Decrease in metabolic functions (mitochondrial
pathways, ROS production and glycolysis),
indicating that the JAK-STAT signaling is a
mediator between inflammation and cellular
metabolism.
(67)
Baricitinib 27 RA samples Tissue culture experiments
on FLS
Abrogation of IFNγ-stimulated FLS invasion by
targeted inhibition of JAK.
(68)
ABT, abatacept; ADA, adalimumab; ANK, anakinra; bDMARD, biologic disease modifying anti-rheumatic drug; ELISA, enzyme-linked immunosorbent assay; ERK, Extracellular signal-
Regulated Kinase; ETN, etanercept; FLS, fibroblast-like synoviocytes; GADD45B, Growth Arrest And DNA Damage Inducible Beta; IHC, immunohistochemistry; IFN, interferon; IFX,
infliximab; JAKi, janus kinase inhibitor; MAPK, mitogen activated protein kinase; MMP, matrix metalloproteinase; MTX, methotrexate; PDE4D, Phosphodiesterase 4D; qPCR, quantitative
polymerase chain reaction; RA, rheumatoid arthritis; RTX, rituximab; SF, synovial fibroblast; STAT, signal transducers and activators of transcription; TCZ, tocilizumab; TNF, tumor
necrosis factor.
(following rituximab inefficacy) associated with subsequent
tocilizumab response (73).
Cell Mediated Therapies
B-Cell Depletion: Rituximab
Treatment with the anti-CD20 monoclonal antibody rituximab
significantly decreases synovial B cells, but, unlike in the
periphery, does not completely eradicate them. In addition,
synovial B cell depletion does not correlate strongly with
clinical response in RA, suggesting the effects of rituximab
on synovial B cells may be necessary but not sufficient
for inducing clinical efficacy (58). A separate study of RA
synovial histology pre- and post-rituximab confirmed these
findings, but also examined changes in other cell populations
at 4 and 16 weeks. A reduction in short-lived CD138+
plasma cells, possibly generated locally within the synovial
membrane, was found to predict clinical response, whilst
delayed reductions in T cell, intimal macrophages and lymphoid
aggregates were also seen, highlighting the role of B cells in
sustaining inflammation and cell recruitment (74). Another
study suggested that clinical response to rituximab is associated
with higher residual levels of CD79+CD20− plasma cells in
the synovium (together with persistence of circultaing ACPA+
IgM plasmablasts) (60). In addition, there is evidence that
baseline synovial gene expression may be able to predict
response to rituximab (and lack of response), as composite
“gene scores” were found to correlate with changes in
disease activity (DAS-28 score) in one study (59). Genes
relating to macrophage and T cell function were activated
in responders.
At a more fundamental level, B cells have shown to be central
to T-cell mediated synovial inflammation. This was elegantly
demonstrated by a study showing that synovial T-cell clones
adoptively transferred into human leukocyte antigen (HLA)-DR-
matched synovial tissues xenotransplanted into severe combine
immunodeficient (SCID) mice are able to enhance local
production of IFNγ, TNF, and IL-1β, but only when transplanted
tissues contain B-cell follicles (75). Furthermore, treatment of
synovial grafts with anti-CD20 depleting agents induces not only
a decrease in B-cell density but also a disruption of the overall
lymphoid architecture and reduction of cytokine expression, as
well as a dramatic depletion of T cells and macrophages, in
keeping with the existence of an active cell network supported
by B cells.
T-Cell Co-stimulation Blockade (Abatacept
(CTLA4-Fc))
Abatacept, a recombinant fusion protein approved for the
treatment of RA, blocks T cell co-stimulation by competing
with CD28 for CD80/86 on antigen presenting cells. Synovial
studies of the effect of and mechanism of abatacept are relatively
lacking. A study of 16 RA patients compared synovial tissue
pre- and 16 weeks post-abatacept in terms of gene expression
and immunohistochemistry. Amongst responders, there was
notable downregulation of several pro-inflammatory mediators,
particularly the T-cell-related cytokine IFNγ. However, only
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a specific reduction in synovial CD20+ B cells without
significant disruption in other cell populations was observed
(contrasting with the observations following anti-cytokine
therapies, perhaps in keeping with the more immunomodulatory
role of CTLA4) (63). Whilst effects on tertiary lymphoid
structures were not analyzed, these observations suggest that
disruption of T-/B-cell interactions may be critical to abatacept’s
mode of action. In contrast to this study, a smaller study
on 5 patients treated with abatacept indicated inhibition
of cell proliferation, with decreases in the expression of
MMP-3, CD68, CD4, CD8, CD20, CD80, and CD86 in the
synovium (64).
Small Molecule Janus-Kinase (JAK)
Inhibitors
Multiple inflammatory cytokines signal via JAK-STAT pathway.
Thus, JAK/STAT signaling plays a key role in several immune
mediated inflammatory diseases, including RA (76). As small
molecules with intracellular targets (i.e., JAK family members),
JAK inhibitors represent a novel targeted therapeutic approach
in RA (77).
Tofacitinib is an oral JAK inhibitor effective for the treatment
of RA (78). It is a pan-selective JAKi, blocking signaling mediated
via JAK1, JAK3 and, to a lesser extent, JAK2 (79). A comparison
of RA synovial tissue at pre- and 4 weeks post-treatment with
tofacitinib showed no change in an overall inflammation score or
levels of T cells, B cells or macrophages, but reduced expression
of MMPs (MMP1 and MMP3) and interferon-regulated genes,
notably CXCL10. Furthermore, clinical improvement at 4
months was found to correlate with reductions in STAT1
and STAT3 phosphorylation, indicating the importance of
IFNγ and IL-6 inhibition, respectively (66). In addition, a
recent metabolomics study showed that adding tofacitinib to
RA synovial explants and synovial fibroblasts in vitro led
to decreased mitochondrial pathway activity, reactive oxygen
species (ROS) production and glycolysis, suggesting modulation
of cellular metabolism may contribute to its therapeutic
effect (67).
Baricitinib, a JAK inhibitor targeting JAK1/JAK2, is
another licensed treatment for RA (80). A study specifically
examining FLS activity in RA showed that baricitinib
abrogates IFNγ-induced invasiveness of FLS (68), which
is of importance given their key contribution to pannus
formation (aggressive cell masses that destroy articular
cartilage and bone), one of the hallmarks of RA synovial
pathobiology (81).
CONCLUSION
It is well-accepted that the considerable advances in the treatment
of RA need to be accompanied by a stratified approach
that mitigates against the current trial and error approach of
treatment decision-making, and the associated individual patient
and health-economic consequences. Significant investment in
biomarker studies has failed to deliver clinically meaningful
tools, with the vast majority focusing on peripheral blood-based
evaluation. The emphasis on synovial tissue, the primary site
of RA is intuitive, from which tissue and thus disease subtypes
are emerging.
The need to pull through benchside investigation of tissue
biomarkers to the bedside demands more refined and innovative
stratified trial design (82). We will soon see the outcomes
of such initiatives [including STRAP—Stratification of Biologic
Therapies for RA by Pathobiology (ISRCTN10618686) and
R4-RA—A Randomized, open labeled study in anti-TNFa
inadequate responders to investigate the mechanisms for
Response—Resistance to Rituximab vs. Tocilizumab in RA
(ISRCTN97443826)] that will inform future tissue driven trial
design. These trials and other tissue-based programmes such as
the recently established NIH Accelerating Medicines Partnership
(AMP) RA/SLE network will also exploit high-dimensional
analyses including mass cytometry, RNA-seq of selected cell
populations, and single cell RNA-seq (83). Whilst the sheer
volume of data in itself presents massive challenges in the
clinically meaningful interpretation, the richness of data matched
with improved sophisticated analytical techniques holds the
promise of being able to join the field of personalized RA targeted
therapy use.
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